Zamtocabtagene autoleucel is under clinical development by Miltenyi Biomedicine and currently in Phase II for Chronic Lymphocytic Leukemia (CLL). According to GlobalData, Phase II drugs for Chronic Lymphocytic Leukemia (CLL) have a 32% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Zamtocabtagene autoleucel’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Zamtocabtagene autoleucel overview

zamtocabtagene autoleucel is under development for the treatment of B-cell Non-Hodgkin’s lymphoma including diffuse large B cell lymphoma, primary (thymic) large mediastinal b-cell lymphoma, follicular lymphoma, mantle cell lymphoma, chronic lymphocytic leukemia, and small lymphocytic lymphoma. It is administered through intravenous route. The therapy comprises of autologous T cells genetically modified to express anti-CD20 and CD19 immunoreceptors. 

Miltenyi Biomedicine overview

Miltenyi Biomedicine, a subsidiary of Miltenyi Biotec GmbH, is a biopharmaceutical company that develops innovative cell and gene therapies and regenerative therapies for cancer treatments.

For a complete picture of Zamtocabtagene autoleucel’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 May 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.